Bioactive metabolites from the leaves of Withania adpressa.

Pharm Biol

a Department of Biology, Faculty of Sciences Semlalia, Laboratory of Biotechnology, Protection and Valorisation of Plant Resources (URAC35 association Unit) , Cadi Ayyad University, Marrakech , Morocco.

Published: December 2018

AI Article Synopsis

  • Withania adpressa Coss. is explored for its antioxidant properties and the specific compounds responsible for inhibiting NF-κB and suppressing multiple myeloma cell growth.
  • Researchers isolated a new compound named wadpressine along with other known withanolides, and assessed their activity through various bioassays.
  • The study found that certain withanolides showed significant potential as anti-cancer agents, particularly in inhibiting NF-κB, which could lead to new treatments for resistant cancers.

Article Abstract

Context: Withania (Solanaceae) species are known to be a rich source of withanolides, which have shown several biological properties.

Objective: To identify the compounds responsible for Withania adpressa Coss. antioxidant activity and further test them for their NF-κB inhibition and antiproliferative activity in multiple myeloma cells.

Materials And Methods: Compounds were obtained from the EtOAc extract of W. adpressa leaves. Structure elucidation was carried out mainly by 1D- and 2D-NMR, and mass spectrometry. Isolated compounds were tested in a dose-response for their in vitro NF-κB inhibition and antiproliferative activity in multiple myeloma cells after 5 and 72 h treatment, respectively.

Results: The fractionation resulted in the isolation of a new glycowithanolide named wadpressine (5) together with withanolide F, withaferin A, coagulin L, and nicotiflorin. The latter showed a moderate ability to scavenge free radicals in DPPH (IC = 35.3 µM) and NO (IC = 41.3 µM) assays. Withanolide F and withaferin A exhibited low µM antiproliferative activity against both multiple myeloma cancer stem cells and RPMI 8226 cells. Furthermore, they inhibited NF-κB activity with IC values of 1.2 and 0.047 µM, respectively. The other compounds showed a moderate inhibition of cell proliferation in RPMI 8226 cells, but were inactive against cancer stem cells and did not inhibit NF-κB activity.

Discussion And Conclusions: One new glycowithanolide and four known compounds were isolated. Biological evaluation data gave further insight on the antitumor potential of withanolides for refractory cancers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6249549PMC
http://dx.doi.org/10.1080/13880209.2018.1499781DOI Listing

Publication Analysis

Top Keywords

antiproliferative activity
12
activity multiple
12
multiple myeloma
12
withania adpressa
8
nf-κb inhibition
8
inhibition antiproliferative
8
withanolide withaferin
8
cancer stem
8
stem cells
8
rpmi 8226
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!